CyberKnife Stereotactic Body Radiation Therapy as an Effective Treatment for Hepatocellular Carcinoma Patients With Decompensated Cirrhosis

Sun, Jing; Zhang, Aimin; Li, Wengang; Wang, Quan; Wang, Jia; Fan, Yuze; Sun, Ying-Zhe; Li, Dong; Zhang, Dan; Duan, Xiaojiang

doi:10.3389/fonc.2020.00100

Cited by 5 publications

(4 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous retrospective study [3] showed that for the HCC patients with decompensated cirrhosis, the overall survival rates of 1-year, 2-year and 3-year were 84.4%, 61.8% and 46.0%, respectively. The local control rates of 1 year, 2 years and 3 years were 92.9%.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients with Decompensated Cirrhosis: protocol of study

Sun

Liu

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: There is a lack of data on the safety and the efficacy of stereotactic body radiotherapy in small hepatocellular carcinoma (HCC) patients with decompensated cirrhosis, and this study was conducted to explore on this field.Methods: This study is designed as a mono-center study. The participants who were diagnosed with HCC and decompensated cirrhosis received Cyberknife stereotactic body radiation therapy (CK-SBRT). The primary outcome measures are to calculate overall survival rates (OS), progression-free survival rates (PFS) and local control rates (LC). The secondary outcome measures are to observe radiation-induced liver injury (RILD) rates after CK-SBRT. Moreover, adverse reactions are also observed.Discussion: HCC patients’ options of treatments were limited by poor liver function. CK-SBRT may offer an option for these patients. We propose to conduct a study to explore the efficacy and adverse reactions of CK-SBRT in treating HCC patients with decompensated cirrhosis (≤5 cm). The trial protocol has been approved by the Institutional Review Board of 302 Hospital of PLA (People’s Liberation Army). The Ethics number is 2020062D.Trail registration: Clinical trails number: NCT04512833. Date of registration: August, 2020. https://clinicaltrials.gov/show/NCT04512833

show abstract

Section: Discussionmentioning

confidence: 97%

“…Stereotactic body radiation therapy (SBRT) has been an effective treatment for HCC patients, and our previous study [3] showed SBRT may provide new options for the treatment of decompensated cirrhosis patients. However, because the sample volume of our previous study was small and it was a retrospective study, the result may be biased.…”

Section: Introductionmentioning

confidence: 99%

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients with Decompensated Cirrhosis: protocol of study

Sun

Liu

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with the portal vein invasion are di cult to perform surgery, some other effective and safe options are needed. We have proven that Cyber-Knife SBRT (CK-SBRT) is safe for HCC patients with decompensated cirrhosis 4 , and we also found that the platelet count was an in uencing factor that affected the survival rates of patients with small HCC (including all patients who received CK-SBRT and hepatic resection) 5 . Therefore, we conducted this study to evaluate the e cacy and safety of stereotactic body radiation therapy (SBRT) in patients with the portal vein invasion (≤ 5 cm) and explore the association between pretreatment platelet count and out-eld recurrence and radiation-induced liver disease (RILD).…”

Section: Introductionmentioning

confidence: 91%

The efficacy and markers of recurrence of stereotactic body radiation therapy alone for hepatocellular carcinoma with the portal vein invasion (≤5 cm)

Sun

et al. 2023

Preprint

Self Cite

View full text Add to dashboard Cite

Background and Aims: To evaluate the efficacy and safety of stereotactic body radiation therapy (SBRT) in patients with the portal vein invasion (≤5 cm) and explore the association between pretreatment platelet count and out-field recurrence and radiation-induced liver disease (RILD). Methods: A total of 490 HCC patients whose single lesion with the portal vein invasion (≤5 cm) treated with SBRT were included in our study. 334 patients were retrospectively enrolled and 156 patients were prospectively included in our investigation respectively. Results: The 1-, 3- and 5-year overall survival (OS) rates were 96.7%, 80.6% and 72.3%, respectively. The 1-, 3- and 5-year progression free survival (PFS) rates were 80.5%, 58.4% and 45.1%, respectively. The 1-, 3- and 5-year distant metastasis-free survival (DMFS) rates were 82.2%, 61.8% and 48.3%, respectively. The 1-, 3- and 5-year local control (LC) rates were 98.2%, 95.1% and 93.5%, respectively. A lower pretreatment PLT count was found to be associated with worse OS rates (HR 0.990, 95% CI 0.985-0.996, p=0.001*), PFS rates (HR 0.995, 95% CI 0.993-0.998, p=0.001*) and higher occurrence rates of RILD (HR 0.978, 95% CI 0.965-0.991, p=0.001*). Conclusions: SBRT was a safe and effective option in patients with the portal vein invasion (≤5 cm), which had shown good LC, OS rates and low toxicity. The platelet count could predict out-field recurrence and RILD.

show abstract

“…Combining TACE with systemic therapy has not so far shown significant improvement compared to TACE alone but further clinical trials are ongoing. Additional locoregional treatments include the stereotactic body radiotherapy "cyberknife" and targeted chemotherapy using Yttrium microspheres [112,113].…”

Section: Non-curative Treatmentsmentioning

confidence: 99%

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

Phoolchund,

Khakoo

2024

Cancers

View full text Add to dashboard Cite

Metabolic-dysfunction-associated steatotic liver disease (MASLD, previously known as non-alcoholic fatty liver disease (NAFLD)) represents a rapidly increasing cause of chronic liver disease and hepatocellular carcinoma (HCC), mirroring increasing rates of obesity and metabolic syndrome in the Western world. MASLD-HCC can develop at an earlier stage of fibrosis compared to other causes of chronic liver disease, presenting challenges in how to risk-stratify patients to set up effective screening programmes. Therapeutic decision making for MASLD-HCC is also complicated by medical comorbidities and disease presentation at a later stage. The response to treatment, particularly immune checkpoint inhibitors, may vary by the aetiology of the disease, and, in the future, patient stratification will be key to optimizing the therapeutic pathways.

show abstract

CyberKnife Stereotactic Body Radiation Therapy as an Effective Treatment for Hepatocellular Carcinoma Patients With Decompensated Cirrhosis

Cited by 5 publications

References 27 publications

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients with Decompensated Cirrhosis: protocol of study

CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients with Decompensated Cirrhosis: protocol of study

The efficacy and markers of recurrence of stereotactic body radiation therapy alone for hepatocellular carcinoma with the portal vein invasion (≤5 cm)

MASLD and the Development of HCC: Pathogenesis and Therapeutic Challenges

Contact Info

Product

Resources

About